HELP · Cybin Inc.

Current Thesis

Helus Pharma’s revaluation rests on HLP003 confirming its antidepressant effect in the APPROACH Phase 3 trial during Q4 2026, before the market loses the previously identified $11.78 support shelf. Success requires statistically significant improvement against placebo at the primary endpoint, supported by durability and safety results; enrollment completion alone does not settle the case.

September has brought fresh coverage rather than the headline drought described on September 5. Barclays initiated coverage with an Overweight rating and a $35 analyst price target on 2026-09-18, according to Benzinga’s analyst-action record. At the 2026-09-14 H.C. Wainwright conference, CEO Michael Halstead retained Q4 2026 timing without specifying a release date. Management transcript

The inference is that the narrative is maturing — the September 14 presentation reiterated the clinical timetable, while September 18 added analyst attention without resolving efficacy. This assessment would change if a company announcement supplied pivotal results or a firm readout date. The case remains a single-name clinical binary; the available evidence does not establish a current squeeze.

Bullish and bearish views on Cybin Inc.

The model's bull view on Cybin Inc. (HELP), in brief: Enrollment uncertainty has narrowed. Helus announced on 2026-07-21 that APPROACH had completed enrollment ahead of schedule with 223 adults. The study compares HLP003 with placebo in major depressive disorder alongside existing antidepressant treatment; completion establishes a… The bear view: Fresh coverage met a reversal. Reporting on 2026-09-18 described an opening advance followed by an intraday reversal despite Barclays’ initiation. That session establishes a weak response to favorable coverage; one observation cannot establish persistent distribution or… Both cases follow in full.

Bull Case

• Enrollment uncertainty has narrowed. Helus announced on 2026-07-21 that APPROACH had completed enrollment ahead of schedule with 223 adults. The study compares HLP003 with placebo in major depressive disorder alongside existing antidepressant treatment; completion establishes a development milestone, not efficacy. Company announcement filed with the SEC
• The upcoming result tests durability. At the 2026-09-14 conference, management said topline disclosure would include the six-week primary endpoint, twelve-week secondary endpoint and safety data. Those measurements can test whether an initial antidepressant effect persists; failure against placebo would invalidate the clinical leg. Management transcript
• Analyst attention has expanded. Barclays’ 2026-09-18 initiation followed TD Cowen’s 2026-08-20 increase in its analyst price target from $8 to $62. These are attributable valuation opinions, not measured probabilities of trial success. Benzinga analyst actions

Bear Case

• Fresh coverage met a reversal. Reporting on 2026-09-18 described an opening advance followed by an intraday reversal despite Barclays’ initiation. That session establishes a weak response to favorable coverage; one observation cannot establish persistent distribution or narrative saturation. September 18 market report
• Cash consumption remains material. The 2026-08-14 financial release reported $166.4 million in cash at 2026-06-30 and $37.1 million of operating cash used during the quarter, compared with $29.5 million a year earlier. Management still had not supplied long-term runway guidance at its September 14 presentation. No runway duration can be established from those figures alone. Fiscal Q1 release, management transcript
• Readout timing remains a window. Asked directly about timing on 2026-09-14, Halstead retained the fourth-quarter window. TD Cowen’s August 20 mid-November expectation remains an analyst estimate, not a company appointment. No APPROACH topline disclosure by 2026-12-31 would break the timing component of the thesis. Management transcript

Setup & Price Structure

The adjusted daily series records a $12.37 close on 2026-09-18, a three-month price increase of 155.1%, and a fourteen-day relative strength index (RSI) of 51.2. The same reference series places the shares 11.8% below its $14.02 annual high. These are measured price statistics; they do not demonstrate accumulation or forecast a clinical result.

The $11.78–$12.05 shelf identified in the 2026-09-05 published analysis supplies the structural reference. Its lower boundary is retained as an explicitly historical research level, not presented as newly verified support. A daily close below $11.78 would break the support condition attached to this thesis.

Benzinga’s 2026-09-10 healthcare momentum screen described an RSI above 70, while the September 18 reference reading is 51.2. The dated observations show that the earlier overbought description is stale. The September 18 options-activity headline supplies no directional exposure figures, and current short-interest and moving-average measurements are missing; neither institutional accumulation nor squeeze pressure is established.

Catalyst Calendar (next 30 days)

For 2026-09-20 through 2026-10-19, no confirmed day-specific earnings or APPROACH results announcement is established by the available calendar evidence. The September 11 Cantor appearance has elapsed.

• 2026-09-30: Development guidance checkpoint. The 2026-08-14 release guided completion of the next HLP004 study design during Q3 2026. September 30 is the quarter-end checkpoint, not a scheduled presentation or data release; on September 14, management said design work was still being finalized. This milestone concerns the anxiety program and does not settle the HLP003 thesis. Fiscal Q1 release, management transcript
• ~2026-11-15, estimated: APPROACH topline. This indicative date reflects TD Cowen’s 2026-08-20 mid-November expectation cited in the September 5 coverage. The company’s September 14 statement remained Q4 2026. This later event is included because efficacy, durability and safety determine the clinical case. Management’s timing statement

What Would Change Our Mind

Loss of the September 5 shelf would end the structural case: a daily close below $11.78 is the observable price invalidation. Independently, failure to achieve statistically significant benefit against placebo on APPROACH’s six-week Montgomery–Åsberg Depression Rating Scale (MADRS) primary endpoint would invalidate the efficacy thesis. Failure at the twelve-week secondary endpoint would undermine the durability component specified in the July 21 trial announcement.

The positive case requires reported primary-endpoint success accompanied by supportive durability and safety findings before price invalidation. Analyst target increases do not meet that condition. An explicit postponement beyond Q4 2026, or the absence of topline results by 2026-12-31, would invalidate the published timing assumption.

Correlation Notes

The earlier coverage recorded HELP alongside ATAI and CMPS in healthcare-gainer screens on 2026-07-16, and TD Cowen’s 2026-08-20 rationale included sector developments. Those dated observations identify a possible shared psychedelic-drug narrative, but the sample is too small to support a correlation estimate or a claim of stable cohort behavior. This remains a single-name setup whose central test is APPROACH; a peer rally cannot establish HLP003 efficacy.